

5 September 2023

ASX Code: MXC

LSE Code: MXC

## Results of Shareholder's General Meeting

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

**MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company')** would like to announce the results from the Company's General Meeting of Shareholders held today, Tuesday, 5 September 2023, in accordance with ASX Listing Rule 3.13.2.

The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried.

Details of the proxy voting and voting outcomes for all motions put to the meeting are set out in the attached report.

—Ends—

**Authorised for release by the Company Secretary, for further information please contact:**

**MGC Pharmaceuticals Ltd**

Roby Zomer  
CEO & Managing Director  
+61 8 6555 2950  
[info@mgcpharma.co.uk](mailto:info@mgcpharma.co.uk)

**UK IR/PR Advisers**

**IFC Advisory**  
Graham Herring / Tim Metcalfe / Zach Cohen  
+44 203 934 6630  
[mgcpharma@investor-focus.co.uk](mailto:mgcpharma@investor-focus.co.uk)

**MGC Pharmaceuticals Ltd**

Rowan Harland  
Company Secretary  
+61 8 6555 2950  
[info@mgcpharma.co.uk](mailto:info@mgcpharma.co.uk)

**UK Brokers**

**Oberon Capital**  
Aimee McCusker / Adam Pollock  
+44 203 179 5300  
[aimeemccusker@oberoninvestments.com](mailto:aimeemccusker@oberoninvestments.com)  
[adampollock@oberoninvestments.com](mailto:adampollock@oberoninvestments.com)

### About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant derived medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil, and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

*Follow us through our social media channels:*

Twitter: @MGC\_Pharma  
Facebook: @mgcpharmaceuticals  
LinkedIn: MGC Pharmaceuticals Ltd.  
Instagram: @mgc\_pharma

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Approval to issue SPP and Shortfall Options	Ordinary	628,820,285 91.47%	52,168,300 7.59%	6,486,122 0.94%	3,120,601	635,388,567 92.41%	52,168,300 7.59%	3,120,601	Carried
2 Approval to issue Shares under the Shortfall Offer	Ordinary	667,070,367 90.70%	52,930,682 7.20%	15,491,400 2.10%	3,154,979	683,178,709 92.81%	52,930,682 7.19%	3,154,979	Carried
3 Issue of SPP Options to Related Party - Roby Zomer	Ordinary	620,898,511 89.22%	59,103,621 8.49%	15,966,182 2.29%	42,679,114	Withdrawn			

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.